Brooklyn ImmunoTherapeutics, Inc.
(NYSE Amex Equities : BTX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.93%169.770.7%$1345.09m
PFEPfizer Inc. 1.15%40.150.9%$1312.60m
MRKMerck & Co., Inc. 0.64%78.500.7%$923.31m
ABBVAbbVie, Inc. 1.67%116.881.9%$729.05m
BMYBristol-Myers Squibb Co. 0.91%65.121.0%$723.23m
LLYEli Lilly & Co. 1.39%195.021.1%$577.79m
AZNAstraZeneca Plc 1.01%55.051.2%$547.87m
BTXBrooklyn ImmunoTherapeutics, Inc. 4.90%28.7312.8%$330.24m
GSKGlaxoSmithKline Plc 0.65%38.590.2%$188.10m
NVSNovartis AG 0.71%88.200.2%$172.69m
VTRSViatris, Inc. 0.17%15.750.0%$166.01m
CVACCureVac NV 2.77%96.560.0%$142.69m
SNYSanofi 1.04%52.310.2%$70.75m
NVONovo Nordisk A/S 0.73%78.610.1%$70.62m
ATNXAthenex, Inc. 2.75%4.850.0%$59.77m

Company Profile

Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.